Safety and Immunogenicity of Recombinant Zoster Vaccine for Transplant Recipients
Eligible age
18+ yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this clinical trial is to compare responses to Varicella Zoster vaccination between transplant patients on different medication regimens, and their healthy co-habitants. The main questions it aims to answer are: 1. Are there differences in vaccination immunological responses in transplant patients on different immunosuppression regimens? 2. Are there differences in vaccination immunological responses between transplant patients and their healthy co-habitants? Participants will all receive a 2-dose course of SHINGRIX recombinant Zoster vaccination, and have immunological responses measured and compared at 5 timepoints between 1 week to 1 year post-vaccination.
Sponsor: Central Adelaide Local Health Network Incorporated
You may qualify if…
- ✓ Household co-habitant of transplant recipient in trial
- ✓ Aged \>50 years
- ✓ Previous documented infection with VZV (known infection history or positive VZV IgG result)
- ✓ Organ transplant recipients
- ✓ \-- Specific immunosuppression regimen
- ✓ Tacrolimus, mycophenolate, prednisolone (n = 30, Group 2)
- ✓ Tacrolimus, mTORi, prednisolone (n = 30, Group 3)
- ✓ mTORi, mycophenolate, prednisolone (n = 30, Group 4)
You may not qualify if…
- ✕ Aged \<50 years
- ✕ Unable or unwilling to provide informed consent to participate in the trial
- ✕ Known allergy to or intolerance of the contents of the RZV vaccine
- ✕ No previous infection with VZV (chickenpox)
- ✕ History of primary immunodeficiency, documented vaccine hypo-responsiveness, or active immunosuppressive therapy
- ✕ 2. Population - Groups 2-4. Transplant recipients (n = 90)
- ✕ Aged \<18 years
- ✕ Unable or unwilling to provide informed consent to participate in the trial
Source: ClinicalTrials.gov · NCT06262776 · last updated 2026-04-09